Wednesday, 22 June 2011
12:30
Expert discussion (by invitation only): Adjuvant treatment of colon cancer
Scientific committee and selected experts Room 120-121
Session I: Selected abstracts I
Chairs: Mario Dicato, MD and Eric Van Cutsem, MD, PhD 15:00
Welcome and introduction: Congress Chairs and ESMO President
Mario Dicato, MD, Eric Van Cutsem, MD, PhD, and David J. Kerr, MD, FRCP, FRCGP 15:05
Presentation of selected abstracts
Early tumor shrinkage and long-term outcome in metastatic colorectal cancer: Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies
H. Piessevaux, et al., O-0015
Implications of variability in the frequency of pharmacogenetic genotypes between Asians and Caucasians for treatment outcomes in colorectal cancer
M. Loh, et al., O-0003
The TGF B (beta) R1 gene has a highly significant mutation frequency at several single nucleotide polymorphism (SNP) marker sites in Caucasian patients with advanced colorectal cancer as compared to healthy controls
M. Pauly, et al., O-004
One-year follow-up data for catumaxomab as part of a multimodal approach in patients with primarily resectable gastric cancer
C. Schuhmacher, et al., O-0005
Subgroup analysis of patients with colorectal neuroendocrine tumors (NET) in the phase III RADIANT-2 study comparing everolimus plus octreotide LAR with placebo plus octreotide LAR
D. Castellano, et al., O-0006
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capectiabin in metastatic or locally recurrent gastric cancer
P. Rougier, et al.
Session II: Cancer of the pancreas and bile ducts
Chairs: Margaret A. Tempero, MD and Volker Heinemann, MD, PhD
16:00
Diagnostic challenges in pancreatic tumors
Thomas Seufferlein, MD, PhD
16:20
Can borderline resectable or non-resectable pancreatic cancer become resectable after a neoadjuvant treatment?
Volker Heinemann, MD, PhD
16:40
One year after FOLFIRINOX data for pancreatic cancer: How relevant is the data?
Margaret A. Tempero, MD
17:00
Cases of pancreatic cancer: Adjuvant, locally advanced, and metastatic disease
Volker Heinemann, MD, PhD and Eileen M. O’Reilly, MD 17:20
Presentation of selected abstracts
Improved 6-month survival rate in subjects with prostate stem cell antigen positive tumors in a global, randomized phase 2 trial comparing gemcitabine vs. gemcitabine + AGS-1C4D4 (ASP6182) in metastatic pancreatic cancer
M. Hidalgo, et al., O-0007
hENT1 and dCK expression predict benefit from gemcitabine after curative-intent resection in pancreatic adenocarcinoma
R. Marechal, et al., O-0008
Phase I/II Study with monotherapy of trabedersen (AP 12009): Encouraging survival results for patients with metastatic pancreatic cancer
P. Kiessling, et al., O-0009
17:50
Molecular pathogenesis and new therapeutic targets in pancreatic cancer
Manuel Hidalgo, MD, PhD 18:10
New treatment options on the horizon in pancreatic cancer and cholangiocarcinoma
Eileen M. O’Reilly, MD 18:30
Surgery for bile duct cancer
Thomas Grüenberger, MD 19:00
Adjourn
CLOSED SESSION (by invitation only)
Parallel with Session II: Cancer of the pancreas and bile ducts 16:00
Strategy of national and international clinical trial groups
Presentation of colorectal cancer and GI cancers program/strategy
Rooms 120-121
19:30
Adjourn closed session
Thursday, 23 June 2011
CLOSED SESSION (by invitation only)
Parallel with Session III: Meet the expert concurrent presentations and Session IV: Cancer of the liver
8:00
How to go forward with translational research in GI cancer
Discussion on collaboration and strategy
Rooms 124-125
Session III: Meet the expert concurrent presentations
8:00
Anal cancer
Robert Glynne-Jones, MBBS, FRCR, FRCP
Rooms 118-119
Cholangiocarcinoma and gall bladder cancer
John Bridgewater, MD, PhD
Rooms 120-121
Supportive care: Management of anemia and emesis– guidelines
Mario Dicato, MD
Rooms 122-123
GIST
John R. Zalcberg, MD, PhD, FRACP
Rooms 127-128
Reading or interpreting the medical literature
Daniel G. Haller, MD
Rooms 129-130
New radiation techniques: Technical and clinical analysis Karin Haustermans, MD, PhD
Rooms 131-132
Session IV: Cancer of the liver
Chairs: Jordi Bruix, MD and Philippe Rougier, MD, PhD
9:00
Presentation of selected abstract
Use of antiviral therapy in surveillance: The impact on the outcome of hepatitis B-related hepatocellular carcinoma
S. Chan, et al., O-0010
9:10
Molecular changes occurring in pathogenesis of hepatocellular carcinoma (HCC)
Chris Verslype, MD, PhD
9:30
Treatment algorithm in HCC
Jordi Bruix, MD, PhD
9:50
New agents on the horizon in HCC
Andrew X. Zhu, MD, PhD
10:05
Keynote lecture 1: Liver transplantation in HCC
Vincenzo Mazzaferro, MD 10:30
Break and poster viewing (abstracts to be presented: clinical/basic non-CRC abstracts)
Session V: Rare tumors—Neuroendocrine tumors and gastrointestinal stromal tumors (GIST)
Chairs: Eric Van Cutsem, MD, PhD and John R. Zalcberg, MD, PhD, FRACP 11:00
What is new after imatinib for GIST?
John R. Zalcberg, MD, PhD, FRACP 11:15
Clinical and pathological classification of neuroendocrine tumor (NET)
Guido Rindi, MD, PhD 11:35
Medical treatment of NET
Philippe Ruszniewski, MD 11:55
Presentation of selected abstract
Everolimus improves progression-free survival (PFS) regardless of baseline chromogranin A (CgA) and neuron-specific enolase (NSE) levels in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3)
M. Pavel, et al., O-0011
12:10
NET tumor board
Guido Rindi, MD, PhD, Philippe Ruszniewski, MD and
Marianne Pavel, MD 12:30
Session adjourns 12:45
Concurrent luncheon symposia begin 14:15
Concurrent luncheon symposia adjourn
Session VI: Esophageal cancer
Chairs: Karin Haustermans, MD, PhD and Christophe Mariette, MD, PhD 14:30
Treatment of Barrett’s esophagus
Jacques J. Bergman, MD, PhD 14:50
Surgery for esophageal cancer: For which patients is the best treatment a single modality treatment?
Jan J. B. van Lanschot, MD, PhD 15:05
Should locally advanced gastroesophageal junction (GEJ) tumors be treated as esophageal cancer or as gastric cancer?
Pro gastric cancer
David Ilson, MD, PhD
Pro esophageal cancer
Karin Haustermans, MD, PhD
15:35
Tumor board: Discussion and cases
David Ilson, MD, PhD, Karin Haustermans, MD, PhD and Christophe Mariette, MD, PhD 15:55
Travel Grant Award Ceremony 16:00
Break and poster viewing (abstracts to be presented: clinical/basic non-CRC abstracts)
Session VII: Gastric cancer
Chairs: Manish A. Shah, MD and Cornelis J.H. van de Velde, MD, PhD 16:30
Carcinogenesis in gastric cancer
Fatima Carneiro, MD, PhD 16:50
What is optimal surgery for gastric cancer?
Cornelis J. H. van de Velde, MD, PhD 17:10
Presentation of selected abstract
Prognostic and predictive factors of the response to adjuvant chemotherapy in resectable gastric cancer: Results from the gastric meta-analysis
S. Morita, et al., O-0012
17:20 Should all patients be treated with adjuvant and/or neoadjuvant treatment?
Roberto Labianca, MD 17:35
What is the reference cytotoxic regimen in advanced gastric cancer?
Andrés Cervantes, MD, PhD 17:50
Presentation of selected abstract
Surrogate endpoints for overall survival in resectable gastric cancer and in advanced gastric carcinoma: Analysis of individual data from the gastric collaboration
P. Rougier, et al., O-0013
18:05
What is the difference in gastric cancer between Asia and the West?
Yoon-Koo Kang, MD, PhD 18:20
What is the optimal algorithm for anti-HER2 targeted therapy in advanced gastric cancer?
Florian Lordick, MD, PhD 18:30
Which new targets are important in gastric cancer?
Manish A. Shah, MD 18:45
Adjourn
Friday, 24 June 2011
Session VIII: Meet the expert concurrent presentations
Parallel with Session IX: Presentation of selected abstracts and Session X: Clinical trials for GI oncologists
8:00
Peritoneal metastases and mesothelioma
Pompiliu Piso, MD
Rooms 118-119
Carcinoma of unknown origin
Nicholas A. Pavlidis, MD, PhD
Rooms 120-121
ESSO session on surgery: Liver resection and ablation techniques
Graeme J. Poston, MD
Rooms 122-123
ESDO session: The new European guidelines on colorectal cancer screening
Lawrence von Karsa, MD
Rooms 129-130
Session IX: Selected abstracts II
Chair: Fortunato Ciardiello, MD, PhD
Parallel with Session VIII: Meet the expert concurrent presentations and Session X: Clinical trials for GI oncologists
8:00
Presentation of selected abstracts
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-RAS unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07)
R. Winterhalder, et al., O-0014
Assessment of tumor genotypes in metastatic colorectal cancer (mCRC): Mutations beyond KRAS codons 12 and 13 as predictive biomarkers of response to panitumumab (pmab) in a randomized, phase 3 study
M. Peeters, et al., O-0016
Randomized, double-blind, placebo-controlled phase 2 study of AMG 386 plus FOLFIRI in patients with previously treated metastatic colorectal carcinoma (mCRC)
M. Peeters, et al., O-0017
Final results of a multicentre phase II trial assessing sorafenib in combination with irinotecan as 2nd or later-line treatment in metastatic colorectal cancer (mCRC) patients with KRAS mutated tumors (MT) (NEXIRI)
E. Samalin, et al., O-0001
Efficacy of chemotherapy + cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer: Analysis of CRYSTAL and OPUS studies
C. Köhne, et al., O-0002
Session X: Clinical trials for GI oncologists - Trials and endpoints in GI cancer
Chair: Alberto Sobrero, MD and Aimery de Gramont, MD
Rooms 131-132
Parallel with Session VIII: Meet the expert concurrent presentations and Session IX: Presentation of selected abstracts
8:00 Is
DFS, RR or survival the best endpoint in colorectal cancer?
Outcome of ARCAD working group
Marc Buyse, ScD
Which difference should we target?
Alberto Sobrero, MD
Pharmacodynamic endpoints
Josep Tabernero, MD, PhD
9:30
Adjourn session
Session XI: Special nurses’ symposium—EONS symposium: Management of patients with GI cancer
Chairs: Jose San Francisco, RN and
Liesbeth Lemmens, MSc, RN
Rooms 127-128
Parallel with Session XII: ESMO session: Focus on the young medical oncologist
9:00
Optimizing the adherence for targeted therapies
Alessandra Milani, MSc
9:25
Management of side effects associated with targeted therapy
Liesbeth Lemmens, MSc, RN
9:50
Problems of life-style and sexuality and care of stoma/ostomy
Carmen Fuertes Ran, RN and
Maria Dolores Ruiz-Fernandez, RN
10:15
Discussion 10:30
Break and poster viewing (abstracts to be presented: clinical/basic CRC abstracts)
Session XII: ESMO session: Focus on the young medical oncologist
Chairs: David J. Kerr, MD, FRCP, FRCGP and Roberto Labianca, MD
Parallel with Session XI: Special nurses’ symposium— EONS symposium: Nursing aspects on management of side effects of targeted agents
9:00
Towards personalization in gastrointestinal cancer
David J. Kerr, MD, FRCP, FRCGP
9:20
Markers for angiogenesis inhibitors: Lessons learned from the past
Heinz-Josef Lenz, MD, FACP
9:40
Oncogenic mutations and targeted therapies in colon cancer – Have we made progress?
Alberto Bardelli, PhD
10:00
Keynote lecture 2: The ubiquitin proteolytic system and human diseases
Aaron Ciechanover, MD, PhD, Nobel Prize Winner 10:30
Break and poster viewing (abstracts to be presented: clinical/basic CRC abstracts)
Session XIII: Multimodality therapy for rectal cancer
Chair: Vicenzo Valentini, MD 11:00
Imaging in rectal cancer: What is mandatory for optimal staging?
Regina G. H. Beets-Tan, MD, PhD 11:20
Organ sparing-surgery in rectal cancer: How important is it? How can we progress with it?
Andre D’Hoore, MD, PhD 11:35
Is local resection adequate for early rectal tumor (TEMS)?
Emanuele Lezoche, MD 11:50
Presentation of selected abstracts
Preoperative chemoradiotherapy with 5FU/ leucovorin for T3-4 rectal cancer do not increase overall survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question
F. Bonnetain, et al., O-0018
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results of CAO/ARO/AIO-04
C. Rödel, et al.
12:10
Which neoadjuvant treatment to use in rectal cancer?
Claus Rödel, MD 12:25
A glimpse into the future of new radiation techniques for rectal cancer
Vicenzo Valentini, MD 12:40
Is the strategy in the elderly with rectal cancer different?
Robert Glynne-Jones MBBS, FRCR, FRCP 13:00
Adjourn session 13:15
Concurrent luncheon symposia begin 14:45
Concurrent luncheon symposia adjourn
Session XIV: Highlights in cancer
Chair: Mario Dicato, MD 15:00
Keynote lecture 3: Angiogenesis in colorectal cancer
Lee M. Ellis, MD 15:30
Keynote lecture 4: Statistical interpretation in clinical trials
Marc Buyse, ScD 16:00
Keynote lecture 5: Priorities for clinical research in GI cancer
Daniel G. Haller, MD 16:30
Break and poster viewing (abstracts to be presented: clinical/basic CRC abstracts)
Session XV: Adjuvant treatment of colon cancer
Chairs: Hans-Joachim Schmoll, MD, PhD and John L. Marshall, MD 17:00
What is the role and impact of molecular markers on treatment decisions in the adjuvant setting?
Arnaud D. Roth, MD 17:20
Presentation of selected abstract Stroma production within the primary tumor correlates with poor survival for stage I-II colon cancer patients
W. Mesker, et al., O-0019 17:30
Is gene signature based selection ready for clinical use?
David J. Kerr, MD, FRCP, FRCGP 17:45
How to treat a patient with stage III colon cancer in 2011
Aimery de Gramont, MD 18:05
Why did the antibodies fail in the adjuvant treatment?
Heinz-Joseph Lenz, MD, FACP
Session XVI: Poster discussion session
18:25
Poster discussion session I on colon cancer
Alberto Sobrero, MD 18:35
Poster discussion session II on colon cancer
Nadir Arber, MD, MSc, MHA 18:45
Poster discussion on non-colorectal cancer
Julien Taieb, MD, PhD 18:55
Adjourn
Saturday, 25 June 2011
Session XVII: Screening and imaging of colon cancer
Chairs: Nadir Arber, MD, MSc, MHA and
Wolff Schmiegel, MD, PhD
8:30
Screening for colon cancer: Where are we now?
Wolff Schmiegel, MD, PhD
8:50
Colorectal cancer chemoprevention: Ready for practice?
Nadir Arber, MD, MSc, MHA
9:10
Functional imaging for colon cancer Is early response prediction relevant for the clinician?
Dirk Arnold, MD
9:40
Break
Session XVIII: Metastatic colorectal cancer
Chairs: Eric Van Cutsem, MD, PhD and Philippe Rougier, MD 10:10
What is the optimal treatment algorithm for metastatic CRC?
Eduardo Diaz-Rubio, MD 10:25
How long to treat metastatic CRC?
Hans-Joachim Schmoll, MD, PhD 10:40
Presentation of selected abstracts
Amphiregulin and epiregulin expression predicts for treatment efficacy in metastatic colorectal cancer (mCRC) patients treated with cetuximab plus CAPIRI or CAPOX. Analysis of the German AIO CRC Group Trial: KRK-0204
S. Stintzing, et al., O-0020
KRAS mutations and outcome in patients with metastatic colorectal cancer treated with firstline chemotherapy with or without cetuximab
S. Tejpar, et al., O-0021
11:05
Molecular markers beyond KRAS for anti-EGFR and markers for angiogenesis inhibitors
Fortunato Ciardiello, MD, PhD 11:25
Presentation of selected abstracts
Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase III trial (EFC10262-VELOUR)
E. Van Cutsem, et al., O-0024
Primary analysis and biomarker evaluation: Randomized phase Ib/II study of rilotumumab (AMG 102) or ganitumab (AMG 479) with panitumumab versus panitumumab alone in patients (pts) with metastatic colorectal cancer (mCRC)
C. Eng, et al., O-0022
11:45
New drugs on the horizon for CRC – anno 2011
John L. Marshall, MD 12:05
New targets in gastrointestinal cancer
Josep Tabernero, MD, PhD 12:25
Round table discussion 12:45
Adjourn session 13:00
ESO Cancer Observatory begin
The ESO colorectal cancer observatory: Innovation and care in the next 12 months Chair: Mario Dicato Moderator: Alberto Costa
Advances in surgical oncology: Greame Poston
Adjuvant therapy: Eric Van Cutsem
Metastatic disease: Roberto Labianca
Targeted treatment: Fortunato Ciardiello
Advocacy: Hedwig Neesen
14:30
ESO Cancer Observatory adjourn
Session XIX: Liver metastases
Chairs: Bernard Nordlinger, MD and Mario Dicato, MD 14:45
Presentation of ESSO Award 14:45
Surgery for liver metastases: How far should the surgeon go?
Graeme J. Poston, MD 15:10
The multimodal treatment of liver metastases: Frequently asked questions
Bernard Nordlinger, MD 15:30
What is the optimal neo-adjuvant treatment for liver metastases?
Alberto Sobrero, MD 15:50
Presentation of selected abstract
A European multicentre evaluation of survival, safety and liver function after radioembolisation with 90y-resin microspheres (ENRY) for unresectable hepatocellular carcinoma
B. Sangro, et al., O-0023
16:00
Liver directed therapy – a critical analysis: Selective radiotherapy, drug eluting beads or intrahepatic chemotherapy
Michel Ducreux, MD, PhD
Session XX: Report on expert discussion
16:20
Presentation of outcome of expert discussion on adjuvant treatment of colon cancer
Mario Dicato, MD and Eric Van Cutsem, MD, PhD 16:40 Adjourn
|
